Stuart L. Schreiber

This study identifies novel FKBP12 molecular glues and their targets using DNA-encoded libraries, showing FKBP12-dependent recruitment to BRD9 and QDPR.

The paper shows that p53 protein abundance in TP53 mutant cancers can be exploited to selectively kill these cells using proximity-inducing small molecules.

The paper identifies a small molecule, BRD1732, that is ubiquitinated in cells, leading to proteasome inhibition through accumulation of ubiquitin chains.

The paper identifies NXPE1 as an acetyltransferase that modifies mucin glycans in colonic mucus, showing its role in modulating the mucus barrier against commensal microbes in ulcerative colitis.

The paper introduces photo-stereoprobes for expanding the ligandable proteome and demonstrates their use in discovering bioactive small molecules.

This paper describes new bicyclic pyrrolidine inhibitors of Toxoplasma gondii PheRS with improved potency, selectivity, and brain exposure compared to previous azetidine-based inhibitors.

The paper uses base editing to assess the functional impact of cysteine mutations in cancer dependency genes, identifying essential and ligandable cysteines for drug development.

This study shows that lowering prion protein expression with ASOs is effective in treating prion disease across different strains, treatment times, and endpoints.

The paper develops a targeted mass spectrometry method to quantify prion protein in CSF, confirming that reduced PrP levels in prion disease are due to the disease process, not ELISA artifacts.

This study evaluates ELISA-based quantification of PrP in CSF as a biomarker for PrP-reducing therapeutics, showing its reliability and CNS origin.

This paper identifies a vulnerability in clear-cell renal cell carcinoma cells to ferroptosis induced by GPX4 inhibition, driven by the HIF-2-HILPDA pathway and PUFA-lipid enrichment.

The paper introduces the L1000 platform, a high-throughput gene expression profiling method, and reports 1.3 million perturbational profiles expanding the Connectivity Map for drug mechanism discovery and functional annotation.